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Background: A new diagnostic procedure has been established for the selection of
appropriate therapy for small lung lesions. We compared the sensitivity of real-time
multi-slice computed tomography (MSCT) and X-ray television (TV) fluoroscopic
guidance for performing bronchoscopy.
Methods: The first author performed and interpreted all bronchoscopies described
in this study. The diagnosis of malignancy or benign was based on the results of
histopathological examination, as well as clinical and imaging follow-up MSCT. We
also compared the diagnostic yields of lesion size between MSCT and X-ray TV
fluoroscopic guidance.
Results: Real-time MSCT and X-ray TV fluoroscopic guidance was conducted in 82
and 78 patients, respectively. The lesion size detected by real-time MSCT and X-ray
TV fluoroscopic guidance was o10mm (n ¼ 21, 14), 11–15mm (n ¼ 24, 12),
16–20mm (n ¼ 19,14), 21–25mm (n ¼ 9, 12) and 426mm (n ¼ 9, 26). The
sensitivity of real-time MSCT- and X-ray TV fluoroscopic guidance was 62.2% and
52.6%, respectively. The sensitivity of real-time MSCT fluoroscopic guidance for
histopathologic diagnosis of lesions less than 15mm was higher than that of X-ray TV
fluoroscopic guidance. While it was difficult to histopathologically diagnose small
lung lesions less than 10mm in diameter, real-time MSCT fluoroscopic guidance
offers a better chance of such diagnosis, irrespective of the size of the lesion,
compared with X-ray TV fluoroscopic guidance.Elsevier Ltd. All rights reserved.
37 2631; fax: +81 263 36 3722.
shinshu-u.ac.jp (K. Tsushima).
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accurately determine the location of the instruments in relation to the lesion in real
time, thus helping to reduce the number of negative cases.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is the primary cause of cancer death.
The cure rates have remained low because of the
difficulty in detecting early stage disease. Moun-
tain1 reported that stage IA cancer represented 13%
of the total population and that the 5-year survival
rate of patients with such tumors was 61%. Surgical
treatment is expected to be associated with a fairly
high 5-year survival rate for small lung lesion-
so20mm without nodal involvement, or even a
higher rate for those measuring o15mm that are
often free of nodal involvement.2,3 Accordingly, a
diagnostic technique that can detect cancers at an
early stage is needed to reduce the cancer-related
mortality.
Bronchoscopy is a minimally invasive alternative
to surgical procedures for the diagnosis of periph-
eral lung nodules. Previous studies on solitary
pulmonary nodules have consistently shown that
lesion size influences the diagnostic accuracy of
bronchoscopy.4–6 In particular, the yield of broncho-
scopy is low in lesions measuringo20mm located in
the outer third of the lung.7 Thus, other diagnostic
procedures or alternative protocols for the diag-
nosis of small nodules including lung cancers may
be preferable in this situation. Of these, CT-guided
transthoracic needle biopsy could be considered as
a first diagnostic step, especially in very small,
peripheral, and easily accessible lesions. However,
the techniques carry a high risk of complications,
e.g., pneumothorax, and may also be difficult to
conduct depending on the exact location of the
lesion. Since bronchoscopy is a safe procedure with
a low complication rate and allows the examination
of the central airways before operation, it is the
first diagnostic step in our hospital. In this regard,
television (TV) fluoroscopy is limited by the two-
dimensional display format that produces the
overlap of structures, potentially hindering biopsy
of the lung peripheral nodules. On the other hand,
the CT scan has been proposed as a useful guidance
method to provide a cross-sectional view of the
relevant anatomy during the bronchoscopy proce-
dure.8 Real-time multi-slice CT (rMSCT) fluoroscopy
permits real time and precise localization of the
bronchoscope tip and needle.9
In the present study, we report our experience
using rMSCT-guided bronchoscopy, which providesimages in real time, and the usefulness and
diagnostic accuracy of this procedure for peripheral
nodules. We also compared the diagnostic yields of
rMSCT fluoroscopic guidance and X-ray TV fluoro-
scopic guidance for performing bronchoscopy.
Specifically, our study was designed to evaluate
whether this bronchoscopic procedure offers a
possible approach in selected patients.Materials and methods
Bronchoscopist and pathologist
The first author (K.T.) is a pulmonologist with an
extensive 10-year experience in bronchoscopy. In
this study, K.T. performed and interpreted all
bronchoscopies described in this study, including
those on patients of Iiyama Red Cross Hospital. On
the other hand, the histopathological diagnosis was
conducted by the same pathologist (T.H.) at Iiyama
Red Cross Hospital and Azumi General Hospital.
Subjects
Chest CTwas performed as a part of a CT screening
program. Subjects were all patients with well-
defined pulmonary nodules identified by chest CTat
the Azumi General Hospital, who required final
diagnosis by bronchoscopy to select treatments:
surgery and administration of antibiotics, which
were performed between November 2001 and
January 2003. Informed consent was obtained from
each patient prior to the bronchoscopy procedure.
To compare the diagnostic yields of rMSCTand X-ray
TV fluoroscopic guidance for performing broncho-
scopy, we also included patients with peripheral
pulmonary nodules, as identified by chest CT at the
Iiyama Red Cross Hospital, who underwent broncho-
scopy to select treatments between September
1999 and September 2001.
Evaluation prior to bronchoscopy
All patients underwent chest radiography and thin-
section high-resolution CT images before rMSCTand
X-ray TV fluoroscopic guidance for performing
bronchoscopy. The CT images were obtained with
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with a scan rotation time of 0.75 s, using continuous
1-mm collimation slices. The location of the nodule
was determined on the chest CT. The size and
presence of bronchus signs of the lesion were
determined from the findings of chest CT. The
largest dimensions of the lesion parallel and
perpendicular to the bronchus were measured.
The largest perpendicular dimension was used to
define the size of the nodule when calculating the
effect of size on the diagnostic yield.Construction of virtual bronchoscopy
Three-dimensional endoluminal tracheobronchial
simulations can be constructed from thin-section
high-resolution CT scans, which reproduce the
appearances of major endobronchial abnormalities,
as confirmed during bronchoscopy. Virtual broncho-
scopy was constructed using in software (Navigator;
GE Medical Systems, surface rendering method)
based on MSCT images. After the construction of
virtual bronchoscopy for each patient, we imaged
the actual endobronchial findings using virtual
bronchoscopy. We selected the nearest bronchus
to the peripheral nodules before performing
bronchoscopy.rMSCT fluoroscopy
The rMSCT fluoroscopy (10mA, 120 kV, 2-mm sec-
tion thickness, 0.75 s of rotation) was performed
with real-time visualization to help confirm the
location of the transbronchial brush, needle aspira-
tion and biopsy forceps. For all patients, the use of
a 10mA technique was sufficient to achieve good
image quality and to perform bronchoscopy. The
patient was placed head first into the scanner, with
the bronchoscopist to the head of the MSCT table.
The bronchoscope monitor was placed on the same
side of the lung lesion. The radiologist operating
the MSCT fluoroscopy in the same room stood on
the opposite side of the rMSCT fluoroscope monitor.
The rMSCT fluoroscope monitor was positioned on
the same side as the bronchoscope monitor, such
that it was visible to both the bronchoscopist and
radiologist. A button on the control panel per-
mitted the release of the MSCT table, so that the
position of the table could be adjusted by the
radiologists hand in a sliding mode. All physicians
who remained in the room during rMSCT fluoro-
scopic imaging wore lead aprons. The bronchosco-
pist wore an irradiation monitor on the front of the
chest to measure the radiation exposure. Another
radiologist operating the rMSCT outside of therMSCT room could replay the image sequence. An
rMSCT fluoroscopic image was obtained to correlate
the location of the tip within the target lesions.
The brush, aspiration needle or biopsy forceps were
inserted through the bronchoscope and implanted
in the bronchial wall. The site of implantation was
imaged with rMSCT fluoroscopy to ascertain
whether the tip was directed properly toward the
site of the peripheral lesions. Adjustments were
made using rMSCT fluoroscopic images to insure an
accurate direction, and the instrument was ad-
vanced into the lesion. The biopsy forceps, aspira-
tion needle or brush were directed into the lung
segment. Further selection of the appropriate
subsegmental region was facilitated with rMSCT
fluoroscopic sequences. The location of each
instrument, the number of instruments pass and
the length of time from the start to end of rMSCT
scanning and the amount of overall radiation
exposure against patients and bronchoscopist were
documented. A final rMSCT fluoroscopic image was
obtained to document any complications.
X-ray TV fluoroscopic guidance was performed by
bronchoscopy using the above methods under X-ray
fluoroscopy, and decided the exact position of the
biopsy instrument by changing the patient’s body
position under X-ray fluoroscopy.Bronchoscopy procedure
After administration of 1mg atropine sulfate,
100 mg pethidine hydrochloride and airway anesthe-
sia with 4% lidocaine hydrochloride applied orally,
patients lay on the table of the MSCT scanner.
Arterial oxygen saturation (SpO2) and heart rate
were continuously measured during bronchoscopy
by pulse oximetry. Oxygen was administered via a
nasal cannula and the flow was adjusted upward
from 1 L/min to maintain SpO2 above 90%.
A variety of flexible fiberoptic bronchoscopes
(Olympus, Tokyo); model BF 3C40 (outer diameter;
3.3mm, forceps channel; 1.2mm), and BF P10
(outer diameter; 5.0mm, forceps channel; 2.0mm)
along with their accessories [brushes (BC-201-c-
1006, Olympus), aspiration needles (needle; MAJ-
65, sheath; NA-1c-1, Olympus) and biopsy forceps
(FB-560-1, Olympus)] were used at Azumi general
Hospital and Iiyama Red Cross Hospital. All proce-
dures were performed via the transnasal or
transoral route under local anesthesia. After
visualization of the vocal cords, additional topical
anesthetics were applied as needed. All segments
of the bronchial tree were visualized. The presence
or absence of endobronchial abnormalities was
recorded. The bronchoscope was then advanced
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of the lesion. At first, biopsy forceps using BF 3C40
were advanced into the bronchus under broncho-
scope guidance to accurately determine the loca-
tion of the lesion and performed to obtain at least 2
tissue samples. Next, biopsy using BF P10 was
performed to obtain larger 2 tissue samples. After
the biopsy forceps, the aspiration needle and
brushing were advanced into the lesion, the
brushing and aspiration needles were then with-
drawn. Specimens obtained by biopsy were placed
on glass slides and fixed with 10% formalin. If
bacterial or fungal infection was suspected, the
brush material was smeared on slides, airdried and
processed for Giemsa, acid-fast and PAS staining
and was cultured.Histopathological analysis
Certified cytological technologists blinded to the
bronchoscopic findings first confirmed that an
adequate sample was collected and then conducted
cytological analysis. The diagnosis of malignant
disease was based on the results of histopathologi-
cal analysis of specimens by pathologists also
blinded to the bronchoscopic findings. A diagnosis
of benign disease was based on results of histo-
pathologic examination, as well as clinical and
imaging follow-up MSCTs. Surgical pathological
diagnosis was compared with the bronchoscope
diagnosis in patients who underwent subsequent
resections.Outcome
We divided the final diagnosis into three groups:
Incompletion, Negative and Positive. Incompletion
as a final diagnosis was the case in which rMSCT
fluoroscopic guidance for performing bronchoscopy
could not apparently reach the nodules. Negatives
were cases in which the surgical diagnosis differedTable 1 Lesion characteristics.
Lesion size (mm) rMSCT fluoroscopic guid
o10 21 (1) [3]
11–15 24 (5) [4]
16–20 19 (8) [12]
21–25 9 (4) [2]
425 9 (6) [7]
Total 82 (24) [28]
Data in parentheses are nodules with a positive bronchial sign.
Numbers in square brackets represent cases visible under X-ray fl
rMSCT: real-time multi-slice computed tomography; TV: televisiofrom the bronchoscopy diagnosis although the
biopsy forceps, aspiration needle or brush instru-
ments could apparently reach the nodule(s) under
rMSCT. Positives were cases in which the surgical
diagnosis was similar to that established using
bronchoscopy, or histopathological diagnosis by
bronchoscopy that showed granuloma or an inflam-
matory change, and these findings decreased or
disappeared on follow-up CTs.
Statistical analysis
All values described in the text and tables are
the group mean7standard deviation. One-way
analysis of variance, Student’s unpaired t-test and
Fisher’s exact probability test for independence
were used for comparisons between the groups. A
P-value less than 0.05 was considered statistically
significant.Results
Eighty-two patients were enrolled in the rMSCT
fluoroscopic guidance for performing the broncho-
scopy arm of this study (Table 1). The patient
population consisted of 43 males and 39 females
with a mean age of 65.9712.3 years (range, 20–95
years), and 24 were current or ex-smokers. Of the
82 procedures in which rMSCT fluoroscopy was used
along with bronchoscopy, 82 were directed toward
abnormalities in the peripheral lung fields. Table 2
shows the final diagnosis based on bronchoscopy,
operation, clinical follow-up or follow-up MSCTs.
The final diagnosis was established using broncho-
scope samples in 51 patients (62.2%). Histological
diagnosis showed 27 adenocarcinoma, 1 small cell
carcinoma, 1 large cell carcinoma, 3 atypical
adenomatous hyperplasia, and 1 lymphoangioma.
In 31 patients, bronchoscopy could not assist in
establishing the diagnosis. Thirty-two positiveance X-ray TV fluoroscopic guidance
14 (1) [4]
12 (4) [6]
14 (6) [11]
12 (8) [12]
26 (20) [26]
78 (39) [59]
uoroscopy.
n; BF: bronchoscopy.
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Table 2 Final clinical diagnosis of patients under rMSCT fluoroscopic guidance.
Bronchoscopy Operation Follow-up CTs Therapy
Lung cancer 29 21 2 1
AAH 3 0 0 0
Benign tumor 6 1 0 0
Inflammation 13 0 6 0
Total 51 22 8 1
rMSCT: real-time multislice computed tomography; CT: computed tomography; AAH: adenomatous atypical hyperplasia.
Table 3 Final bronchoscopic results of peripheral lesions under rMSCT fluoroscopic guidance.
Lesion size (mm) Positive Incompletion Negative
o10 9 (1) [2] 10 [1] 2
11–15 13 (5) [3] 6 [1] 5
16–20 12 (4) [8] 5 (2) [2] 2 (2) [2]
21–25 8 (4) [1] 0 1 [1]
425 9 (6) [7] 0 0
Total 51 (20) [21] 21 (2) [4] 10 (2) [3]
rMSCT: real-time multislice computed tomography; data in parentheses are nodules with a positive bronchial sign.
Numbers in square brackets represent cases visible under X-ray fluoroscopy.
Diagnosis yield of ling peripheral module 741cases were diagnosed as malignancy and 19 were
diagnosed as benign. In 8 of these 31 patients,
diagnosis was established by subsequent CTs. The
remaining 22 patients underwent lung lobectomy or
video-assisted thoracic surgery. One patient was
treated with chemotherapy after diagnosis of a
post-operative recurrent lung cancer (Table 2).
Nine of 10 negative cases were diagnosed as
adenocarcinoma and one was a fibrotic change by
surgery. The diagnostic yields that was considered
suspicious for malignancy and benign lesions by
radiologists based on the chest CT findings were
59.3% (32 of 54) and 64.3% (18 of 28), respectively.
The diagnostic yield of bronchoscopy correlated
significantly with the lesion size (Po0:05).
The mean diameter of 82 peripheral lung lesions
was 16.7mm (range: 5–51mm). Twenty-eight of 82
(34.1%) lesions could be detected by X-ray TV-
fluoroscopy. A bronchus transiting the lesion
(bronchus sign) was detected in 24 patients, and
20 of these 24 (83.3%) lesions were diagnosed by
bronchoscopy (Table 3). Positive diagnosis was
made in 51 patients, negative diagnosis in 10
patients and incompletion diagnosis in 21 patients.
Twenty-one of 31 patients who underwent a
nondiagnostic rMSCT CT fluoroscopic guidance were
confirmed to have lung cancer at surgery, and 1
patient was confirmed to have a benign at surgery.
The location of the nodular lesions was 7 in the left
upper, 37 in the right upper lobes, 1 in the linguallobe, 12 in the middle lobe, 9 in the left lower and
16 in the right lower lobe. The morphological data
regarding their nodules were 25 solid nodules, 52
ground glass nodules with high density (mixed
nodular pattern) and 5 pure ground glass nodules
(non-solid nodular pattern) on chest CT scan. In all
patients, re-adjustment using rMSCT fluoroscopy
was required before biopsy, aspiration or brushing.
Table 3 shows the diagnostic yield according to
lesion size:o10mm in diameter, 9 of 21 patients
(42.9%); 11–15mm, 13 of 24 patients (54.2%);
16–20mm, 12 of 19 patients (57.9%); 21–25mm; 8
of 9 patients (88.9%) and425mm in diameter, 9 of
9 patients (100%). The visualization and localization
of the peripheral lesions under rMSCT fluoroscopy
were good and each sampling method (brushing,
aspiration and biopsy) was performed. In 21 of 82
patients, adequate bronchoscopy could not be
performed because we could not accurately loca-
lize the correct bronchial subsegment associated
with the lesion (n ¼ 14) with MSCT fluoroscopy, or
accurately slide the sampling instrument along the
sides of the lesion or through the lesion (n ¼ 5). In
two patients, the ground-glass opacity could be
detected under rMSCT. In 8 patients in whom the
lesion could not be diagnosed and who had under-
went rMSCT fluoroscopic guidance, the lesion
resolved spontaneously, as demonstrated on fol-
low-up CTs.12 In 6 of 8 patients, the nodules or
ground glass opacity disappeared on sequential CTs
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Table 4 Diagnostic yield of bronchoscopy under rMSCT fluoroscopic guidance.
Lesion size (mm) Peripheral lung lesions
rMSCT (diagnosed
number/total number)
X-ray TV (diagnosed
number/total number)
Significance
o10 9/21 (42.9%) 1/14 (7.7%) P ¼ 0:028
11–15 13/24 (54.2%) 2 /12 (20%) P ¼ 0:039
16–20 12/19 (63.2%) 9/14 (64.3%) NS
21–25 8/9 (88.9%) 9/12 (75%) NS
425 9/9 (100%) 20/26 (76.9%) NS
All lesions 51/82 (62.2%) 41/78 (52.6%) NS
Data are numbers and (percentages) of correctly diagnosed cases.
rMSCT: real-time multi-slice computed tomography; TV: television; NS: not significant.
Table 5 Radiation exposure.
Lesion size (mm) Patients Bronchoscopist
Exposure time (s) Radiation exposure (mSv)
o 10 330.37170 9257476 93.5767
10–15 343.77203 9627567 65.1747
16–20 387.37144 10847404 94.8747
21–25 253.5783.1 7107233 43.9728
425 210.47138 5897386 75.1745
Conventional CT 12 474
Conventional with thin-section CT 22 869
Data are mean7standard deviation.
CT: computed tomography.
K. Tsushima et al.742after the administration of broad-spectrum anti-
biotic therapy after rMSCT fluoroscopic guidance.Comparison of X-ray TV and rMSCT CT
fluoroscopic guidance for performing
bronchoscopy
Seventy-eight patients were enrolled in the X-ray
TV fluoroscopic guidance for performing the
bronchoscopy arm of this study. At the Iiyama Red
Cross Hospital, the diagnostic yield of X-ray TV
fluoroscopic guidance in all lesions was 52.6% (41 of
78 patients). The proportions of cases with accu-
rate final diagnoses by X-ray TV fluoroscopic
guidance and rMSCT fluoroscopic guidance for
performing bronchoscopy were not significantly
different. The diagnostic yields of X-ray TV fluoro-
scopic guidance and rMSCT fluoroscopic guidance
for lung lesions were: for lesions o10mm in
diameter, 7.7% and 43%; 11–15mm, 20% and 54%;
16–20mm, 64% and 63%; 21–25mm, 75% and 89%;
426mm in diameter, 77% and 100%, respectively.
These results indicate that the diagnostic yield ofrMSCT fluoroscopic guidance for performing
bronchoscopy was significantly superior to that of
X-ray TV fluoroscopic guidance for lesions measur-
ingo15mm (Po0:001) (Table 4).Radiation exposure
Patients and the bronchoscopist were exposed to a
mean radiation dose of 912.2 mSv (range,
138–2313 mSv) and 75.2 mSv (range, 16–208 mSv),
respectively. The mean time of the rMSCT fluoro-
scopic procedure was 325.8 s (range, 49.3–826 s).
Table 5 shows the radiation dose and time of
bronchoscopy according to lesion size.Complications
No significant bleeding occurred during the pro-
cedures and no dyspnea or ventilatory com-
promise was noted. None of the procedures
resulted in pneumothorax, pneumomediastinum or
bacteremia.
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This study is the first to compare the diagnostic
yields of X-ray TV fluoroscopic guidance and rMSCT
fluoroscopic guidance for performing bronchoscopy,
although it is a historical comparison between the
two techniques. However, this study does not serve
as a control study unless the nodules are truly
matched in terms of their size and location density,
although we assessed the diagnostic yield of rMSCT
fluoroscopic guidance for peripheral nodules, and
compared these results with those of X-ray TV
fluoroscopic guidance conducted by a single physi-
cian (K.T.). However, the present data can show the
use of rMSCT fluoroscopic guidance in patients with
peripheral lung lesions. Compared with CT-guided
percutaneous thoracic needle biopsy, bronchoscopy
has low sensitivity and false negative results. CT-
guided percutaneous thoracic needle biopsy may be
considered as the first diagnostic step, especially
for very small, peripheral and easily accessible
lesions. We did not perform CT-guided biopsy for
peripheral lesions, although the frequency of
pleural dissemination was low. Surgical excision
was also performed for the final diagnosis of lung
cancer. However, some patients were anxious or
refused surgery, or hoped a final diagnosis of the
pulmonary lesion could be made before surgery.
Moreover, some studies showed that CT-guided
bronchoscopy for transbronchial needle aspiration
is a safe and efficient tool for providing diagnostic
material from mediastinal lymph nodes and per-
ipheral nodules.8,9,11 Therefore, we performed
rMSCT fluoroscopic guidance for the diagnosis of
pulmonary lesions and to compare its diagnostic
accuracy with that of X-ray TV fluoroscopic gui-
dance. However, the selected approach depends on
the location and extent of lesions, as well as other
considerations such as referral patterns, expertise
and preferences, in addition to the availability of
the necessary equipment.
In our study, diagnosis was confirmed by biopsy in
51 of 82 patients. This compares favorably with
recent studies in which the overall rate of accurate
diagnosis was 50–70% for lesions of various sizes.7
The sensitivity was markedly better than that of
fiberoptic bronchoscopy conducted by Baaklini et
al.7 who reported a positive bronchial wash in 71 of
177 cases (40%). Our conventional diagnostic
procedures of bronchoscopy included needle as-
piration, brush and transbronchial biopsy. Trans-
bronchial biopsy is the only bronchoscopic method
that allows obtaining a biopsy specimen, hence
allowing diagnosis of benign lesions. Although
transbronchial biopsy is associated with a higher
risk of bleeding and pneumothorax than transbron-chial needle aspiration,12 we performed endobron-
chial biopsy as one of the bronchoscopic procedures
when possible. Consequently, it is possible to
provide a histological diagnosis by the transbron-
chial biopsy. Our results showed certain benefits of
rMSCT fluoroscopic guidance for performing
bronchoscopy. The diagnostic procedure enabled
the detection of small lesions, which could not be
detected by X-ray TV fluoroscopic guidance. It is
important to accurately determine the location of
lesions when planning the biopsy and needle
aspiration, especially for small peripheral lesions
and the lymph nodes adjacent to the major blood
vessels. Transbronchial needle aspiration under the
rMSCT fluoroscopic guidance can visualize the
needle and select an optimal site for needle
penetration and can confirm the depth and angle
of the needle in real time during the procedure.
Although no complications occurred in our study,
we performed a CT sequence immediately upon
completion of the procedure, which would have
permitted immediate detection of and intervention
for pneumothorax or hemorrhage.
The most important drawback of rMSCT fluoro-
scopic guidance for performing bronchoscopy is the
radiation exposure of patients, bronchoscopist and
assistants (Table 5). The potential concern related
to this technique is the use of several minutes of
fluoroscopy. Conventional X-ray TV fluoroscopic
guidance dose parameters are approximately
90 kV and 4mA per second. In comparison, these
parameters are 120 kV and 150mA per second in the
conventional CT fluoroscopy but only 120 kV and
10mA per second in our MSCT fluoroscopy. The dose
used in MSCT fluoroscopy was at least double that
used for conventional X-ray TV-guided fluoroscopy.
In conventional CT, exposure of the entire lung
requires movement of the sliding table in about
12 s, resulting in a maximum skin dose level of
approximately 395 mSv. This time was as much as
22 s, making the maximum skin dose level of
869 mSv in conventional CT combined with thin-
section CT. As shown in Table 5, this radiation
exposure is almost the same as that of rMSCT
fluoroscopic bronchoscopy (mean maximum skin
dose level; 852 mSv, mean bronchoscope procedure
time; 304 s). The bronchoscopist was exposed to a
mean maximum radiation dose of 69.5 mSv. Unlike
conventional fluoroscopy MSCT fluoroscopy employs
a tightly collimated beam (2mm) that confines to a
narrow area. The radiation dose is further dis-
sipated because the sliding table method used in
this procedure limits exposure to any particular
region. Moreover, we reconstructed the virtual
bronchoscopy and selected the precise bronchus
with the nodule before performing bronchoscopy.
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bronchoscopy for guidance during the transbron-
chial biopsy procedures. Their results suggested
that imaging guidance might improve the diagnos-
tic sensitivity for malignant nodule. Although
virtual bronchoscopy provides a ‘‘road map’’ that
could be viewed by the bronchoscopist before
performing bronchoscopy, it does not provide direct
guidance during the procedure. The usefulness of
virtual bronchoscopy is unfortunately limited be-
cause it cannot confirm the correct location of the
peripheral bronchus, due to its limited success in
reconstructing the peripheral bronchi in detail.
However, we believe that virtual bronchoscopy is
beneficial as it shortens the procedure of MSCT
fluoroscopy since the virtual images could correctly
detect fourth-order bronchi under 1-mm collima-
tion high-resolution CT.
rMSCT-fluoroscopic guidance, as well as X-ray TV
fluoroscopy are associated with other risk factors.
The minute specimens obtained by the BF 3C40
procedure make it difficult to establish a definitive
histopathological diagnosis, especially ground-glass
opacity with Noguchi type A and type B or
adenomatous atypical hyperplasia. Lesions de-
tected by chest CT screening mostly appears as
small-diameter lesions. A large proportion of small
nodules do not invade the neighboring bronchus.
Therefore, even with the brush instrument placed
in the center of the lesions, it is difficult to obtain
sufficient material from alveolar-lining tumors.
Specimens obtained by bronchoscopy are only tiny
parts compared with the specimens obtained by
operations, and are unsuitable to assess the
histological grade of the whole lesion apparent on
MSCT. Moreover, it is often difficult to maneuver
the biopsy instruments to reach the site of the
peripheral lesion, due to the limited flexion
inherent in such instruments, compared with brush
instruments. In some cases, the peripheral nodules
could not be accessed by biopsy forceps but could
be reached by the brush instrument. In this study, it
was difficult to make a definitive diagnosis for small
nodules measuringo10mm without bronchial signs,
using rMSCT fluoroscopic guidance. To obtain
samples correctly from noduleso10mm in dia-
meter, it is necessary to place the bronchoscope
at a bronchus adjacent to the nodules, and to
perform transbronchial biopsy. In four small no-
dules measuringo10mm, diagnosis could not be
established using 3C40 bronchoscopy. Instead, we
used ultrathin-bronchoscopy (Olympus BF XP 40,
outer diameter: 2.8mm, forceps channel: 1.2mm)
to improve the approach to the small nodules. That
bronchoscopy allowed the approach of the deep
part of the second-order bronchus better than 3C40bronchoscopy, although no firm diagnosis could be
made in any of these cases. For small nodule-
so10mm in diameter, rMSCT fluoroscopic guidance
showed clearly superior accuracy compared with X-
ray TV fluoroscopic guidance, although the diag-
nostic accuracy of the former procedure is not yet
ideal.
The endoscopic ultrasound-guided bronchoscopy
has been adapted for the central mass and
peripheral nodules. Kikuchi or Kurimoto et al.
reported that even when restricted to peripheral
small nodules o20mm in diameter, the diagnostic
sensitivity of endobronchial ultrasonography with
guide sheath-guided transbronchial biopsy was 53%
or 66%, respectively.14,15 However, US cannot
detect the nodules without solid component less
than 15mm in diameter although the data was not
shown on our hospital. Therefore, the broncho-
scopy under MSCT is more useful to reach a
diagnosis than that under EBUS for the nodules
without solid components less than 15mm in
diameter.
The final problem is the cost-utility of this
technique. We calculated the cost of rMSCT
fluoroscopic guidance for the performance
bronchoscopy to be more expensive by $40 com-
pared with X-ray TV fluoroscopic guidance. The
screening cost for lung cancer by chest CT per
person was $50, based on our 3-year CT screening
program (Asakura et al., Japanese publication,
1999). Surgical excision was also performed for a
final diagnosis of lung cancer. However, some
patients may be anxious or refuse surgery, or hope
a final diagnosis of the pulmonary nodule could be
made before surgery. We commonly used to follow
small nodules by performing serial CTs because its
interval growth would be an indication for surgery.
However, the cost of more than 2 follow-up CTs was
more expensive than that of rMSCT fluoroscopic
guidance. To establish a diagnosis at the time of
first identification may could be more cost-effec-
tive compared with the cost of serial follow-up CTs.Conclusions
Nodules of different sizes could be assessed using
one or more diagnostic procedure. In bronchoscopic
procedures for peripheral nodules, small nodules
less than 10mm should be diagnosed based on CT
morphologic and density characteristics and the
presence or absence of tumor growth tendencies as
determined by serial follow-up CTs because of low
diagnostic sensitivity of rMSCT fluoroscopic gui-
dance for performing bronchoscopy. For lung
ARTICLE IN PRESS
Diagnosis yield of ling peripheral module 745nodules of 10–15mm in diameter and nodules of
16–20mm not clearly visible on X-ray TV, rMSCT
fluoroscopic guidance is a useful procedure based
on the diagnostic sensitivity determined in our
study. For nodules more than 20mm in diameter,
rMSCT- or X-ray fluoroscopic guidance for perform-
ing bronchoscopy could be selected.Acknowledgments
The authors thank the cytologist at our hospital,
Noriyasu Kobayashi. We also thank Kazuaki Akahane
and Masahito Aono for performing MSCT, Megumi
Tominaga and Setsuo Nakajima, assistant nurses,
for their help during bronchoscopy and Kyoko
Nakayama for assistance in collecting bronchoscopy
data at the Iiyama Red Cross Hospital.References
1. Mountain CF. Revisions in the international system for
staging lung cancer. Chest 1997;111:1710–7.
2. Sagawa M, Saito Y, Takahashi S, et al. Clinical and prognostic
assessment of patients with resected small peripheral lung
cancer lesions. Cancer 1990;66:2653–7.
3. Oda M, Watanabe Y, Shimizu J, et al. Extent of mediastinal
node metastasis in clinical stage I non-small-cell lung
cancer: the role of systematic nodal dissection. Lung Cancer
1998;22:23–30.
4. Wallace JM, Deutsch AL. Flexible fiberoptic bronchoscopy
and percutaneous needle lung aspiration for evaluating the
solitary pulmonary nodule. Chest 1982;81:665–70.
5. Fletcher EC, Levin DC. Flexible fiberoptic bronchoscopy and
fluoroscopically guided transbronchial biopsy in the manage-ment of solitary pulmonary nodules. West J Med
1982;136:477–83.
6. Chechani V. Bronchoscopic diagnosis of solitary pulmonary
nodules and lung masses in the absence of endobronchial
abnormality. Chest 1996;109:620–5.
7. Baaklini WA, Reinoso MA, Gorin AB, Sharafkaneh A, Manian P.
Diagnostic yield of fiberoptic bronchoscopy in evaluating
solitary pulmonary nodules. Chest 2000;117:1049–54.
8. Rong F, Cui B. CT scan directed transbronchial needle
aspiration biopsy for mediastinal nodes. Chest
1998;114:36–9.
9. White CS, Templeton PA, Hasday JD. CT-associated trans-
bronchial needle aspiration: usefulness of CT fluoroscopy.
Am J Roentgenol 1997;169:393–4.
11. Goldberg SN, Raptopoulos V, Boiselle PM, Edinburgh KJ,
Ernst A. Mediastinal lymphadenopathy: diagnostic yield of
transbronchial mediastinal lymph node biopsy with CT
fluoroscopic guidance—initial experience. Radiology
2000;216:764–7.
12. Libby DM, Henschke CI, Yankeievitz DF. The solitary
pulmonary nodule: update 1995. Am J Med 1995;99:491–6.
13. McAdams HP, Goodman PC, Kussin P. Virtual bronchoscopy
for detecting transbronchial needle aspiration of hilar and
mediastinal lymph nodes: a pilot study. Am J Roentgenol
1998;170:1361–4.
14. Kikuchi E, Yamazaki K, Sukoh N, et al. Endobronchial
ultrasonography with guide-sheath for peripheral pulmonary
lesions. Eur Respir J 2004;24:533–7.
15. Kurimoto N, Miyazawa T, Okimasa S, et al. Endobronchial
ultrasonography using a guide sheath increases the ability to
diagnose peripheral pulmonary lesions endoscopically. Chest
2004;126:959–65.Further reading
10. Hasegawa M, Sone S, Takashima S, et al. Growth rate of
small lung cancers detected on mass CT screening. Brit J
Radiol 2000;73:1252–9.
